Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| 44.56 | |
| 44.89 | |
| - | |
| 46.86 | |
| 43.105 | |
| 22.11-53.18 | |
| 2 891 M | |
| 65 911 K | |
| 6 072 K | |
| -0.56 | |
| 1.578 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Celldex Therapeutics, Inc. - EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., Ju...
Celldex Therapeutics, Inc. - Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid o...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
